AC Immune SA
ACIU
$2.79
$0.010.36%
NASDAQ
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 33.44M | 32.62M | 32.62M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 33.44M | 32.62M | 32.62M |
| Cost of Revenue | -- | -- | 72.82M | 71.37M | 71.37M |
| Gross Profit | -- | -- | -39.38M | -38.75M | -38.75M |
| SG&A Expenses | -- | -- | 18.54M | 18.85M | 18.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -63.50K | -82.10K | -82.10K |
| Total Operating Expenses | -- | -- | 91.29M | 90.14M | 90.14M |
| Operating Income | -- | -- | -57.85M | -57.52M | -57.52M |
| Income Before Tax | -- | -- | -58.48M | -57.96M | -57.96M |
| Income Tax Expenses | -- | -- | 3.40K | 3.40K | 3.40K |
| Earnings from Continuing Operations | -- | -- | -58.48 | -57.96 | -57.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -58.48M | -57.96M | -57.96M |
| EBIT | -- | -- | -57.85M | -57.52M | -57.52M |
| EBITDA | -- | -- | -56.18M | -55.88M | -55.88M |
| EPS Basic | -- | -- | -0.58 | -0.58 | -0.58 |
| Normalized Basic EPS | -- | -- | -0.36 | -0.36 | -0.36 |
| EPS Diluted | -- | -- | -0.59 | -0.59 | -0.59 |
| Normalized Diluted EPS | -- | -- | -0.36 | -0.36 | -0.36 |
| Average Basic Shares Outstanding | -- | -- | 400.87M | 399.79M | 399.79M |
| Average Diluted Shares Outstanding | -- | -- | 401.89M | 400.81M | 400.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |